Hypermarcas

Hypermarcas

João Alves de Queiroz Filho founded Hypermarcas in 2001, building on the pharmaceutical distribution business his family had operated since the 1960s. The company went public in 2008 after an aggressive acquisition spree that stitched together dozens of Brazilian consumer-product brands. At its peak as a conglomerate, Hypermarcas owned more than 180 household-name products — from diapers and condoms to sweeteners and cough syrup — making it a uniquely recognizable portfolio in Brazilian retail. For most of the 2010s, Hypermarcas was a branded-consumer-goods conglomerate spanning pharmaceuticals, personal care, and food. In the pharma unit, key assets included the prescription brands Cimegripe and Engov as well as the over-the-counter analgesics Doril and Coristina D. The personal-care division owned Sante (hair care), Paixão (condoms), and Jontex (condoms). Food assets included the sweeteners Finn and Zero-Cal and the powdered-beverage brand Frisco. The strategy relied on acquiring under-managed regional brands, centralizing distribution, and buying national television advertising at scale. Starting in 2017, Hypermarcas began divesting its non-pharma assets in a multi-year portfolio simplification. The sweetener brands Finn and Zero-Cal were sold to a Chilean group. The condom business, including the Paixão and Jontex brands, was sold to the Malaysian firm Karex. The food division was dismantled through additional divestments. By 2020, Hypermarcas had concentrated almost entirely on the pharmaceutical segment, exiting the consumer-goods conglomerate model. The company is listed on the B3 stock exchange in São Paulo under the ticker HYPE3. The structural distinctiveness of Hypermarcas is its evolution from a classic Latin American family-conglomerate into a focused public pharmaceutical company — a rare path in a region where diversified holding structures typically persist across generations. The Alves de Queiroz family maintained significant control throughout the metamorphosis, orchestrating the buy-and-sell cycle across two decades without losing operational command.